Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study analyzes best donor match for AML stem cell transplants

NCT ID NCT07155382

Knowledge-focused Sponsor: Asan Medical Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This completed study looked at 98 adults with acute myeloid leukemia (AML) in first remission who received a stem cell transplant from a matched sibling, matched unrelated, or half-matched family donor. All patients got the same chemotherapy conditioning before transplant. Researchers tracked engraftment, graft-versus-host disease, infections, leukemia relapse, and survival to see how donor type and other factors influenced outcomes.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
busulfan, fludarabine, antithymocyte globulin
What this could lead to
If successful, this study could help doctors choose the best donor type and conditioning regimen for AML patients needing a stem cell transplant.
What could go wrong
This is an observational study, not a test of a new treatment. It cannot prove what works best, only suggest patterns. Results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

98 people

The number who actually took part.

Started

Apr 2017

Finished

Aug 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation in first remission

Ages

16 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 3.1. Patients with non-promyelocytic AML, intermediate- or poor-risk categories by NCCN ver 2 (2016) guidelines (Appendix I), who achieve CR after induction chemotherapy. 3.2. Patients should be 16 years of age or more, and 75 years of age or less. 3.4. The performance status of the patients should be 70 or over by Karnofsky performance scale (Appendix II). 3.5. Patients should have adequate hepatic function (bilirubin less than 2.0 mg/dl, AST less than three times the upper normal limit). 3.6. Patients must have adequate renal function (creatinine less than 2.0 mg/dl). 3.7. Patients must have adequate cardiac function (ejection fraction \> 40% on MUGA scan). 3.8. Patients must sign informed consent. Donor selection process (See appendix III) 3.9. Donor selection process may begin before or when the patients achieve CR. 3.9.1. If a patient has a willing HLA-matched sibling of 65 years or younger, that sibling will be a cell donor. 3.9.2. If a patient has no HLA-matched sibling of 65 years or younger, but a willing HLA- matched unrelated donor is available (younger than 55 years as regulated by KMDP), this will be a cell donor. The donor must be matched with the patient for 7-8 of 8 HLA-A, -B, -C, and -DRB1 allele match. 3.9.3. If a patient does not have an HLA-matched sibling nor unrelated donor, but an HLA- haplotype mismatched family member (offspring, parents, haploidentical sibling) available, this will be a cell donor. 3.9.4. Hematopoietic cell donor must sign informed consent. Exclusion Criteria: Patients who do not meet the inclusion criteria \-

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute myeloid leukemia (AML) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute myeloid leukemia (AML)

Contacts and locations

Locations

  • Asan Medical Center

    Seoul, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.